Jordan Safirstein, MD
Cardiovascular Disease · Mountain Lakes, NJNPI 1922265495
Payments from drug & device makers
What this record shows
The money is spread across several categories — food and beverage (50.8%), speaking fees and travel and lodging — rather than concentrated in one kind of arrangement. 60 manufacturers reported payments, led by Medtronic at 24.1% of the total. Among cardiovascular disease clinicians in NJ with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 718 payments — averaging $61.12 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Medtronic$11K
- Shockwave Medical, Inc$9K
- Edwards Lifesciences$4K
- ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$4K
- Abbott$3K
- Boston Scientific$2K
- plus $11K from 54 others
Across 49 payments — averaging $5056.15 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Cathworks, Inc.$120K
- Biolife, L.L.C.$50K
- M.a. Med Alliance S.A.$38K
- Spectrawave, Inc$21K
- Cardiovascular Systems Inc.$13K
- Abbott$3K
- plus $2K from 1 others
What the payments were for
- Speaking & faculty fees$18,60042%
- Travel & lodging$2,6776%
- Food & beverage$22,31151%
- Entertainment$150%
- Other$2821%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- CoreValve Evolut$8,902
- Shockwave IVL System with the Shockwave C2 Coronary IVL Catheter$8,743
- LifeVest$4,000
- Diamondback Coronary$613
- Coronary Orbital Atherectomy System$566
- OPTIS$539
- HyperVue Imaging System$480
- Starlight Imaging Catheter$480
- Impella$391
- DRAGONFLY OPSTAR$388
- COREVALVE EVOLUT R$324
- GUIDELINER$289
- AVVIGO Guidance System$283
- PORTICO$282
- Edwards SAPIEN 3 Ultra Transcatheter Heart Valve$231
- XIENCE SKYPOINT$147
- Emerge Push$145
- Optis Coronary Imaging System$136
- CVI SYSTEMS$132
- METACROSS OTW$130
How this compares
$43,885 in reported general payments places this provider in the 95th percentile of 1,006 cardiovascular disease providers in New Jersey.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 237 | $261,825 |
| XareltoRivaroxaban | 142 | $161,675 |
| Repatha SureclickEvolocumab | 41 | $40,976 |
| EntrestoSacubitril/Valsartan | 28 | $22,971 |
| BrilintaTicagrelor | 17 | $16,139 |
| FarxigaDapagliflozin Propanediol | 15 | $12,721 |
| Metoprolol Succinate | 533 | $7,640 |
| Nebivolol Hcl | 59 | $5,810 |
| Rosuvastatin Calcium | 329 | $4,675 |
| Atorvastatin Calcium | 282 | $2,688 |
| Torsemide | 103 | $2,462 |
| Losartan Potassium | 173 | $2,283 |
| Prasugrel Hcl | 14 | $1,940 |
| Amlodipine Besylate | 212 | $1,703 |
| Valsartan | 47 | $1,688 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $528 | $261,825237 claims |
| Johnson & JohnsonXarelto | $197 | $161,675142 claims |
| AstraZenecaBrilinta, Farxiga | $358 | $28,86032 claims |
| NovartisEntresto | $778 | $22,97128 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 1,006 cardiovascular disease providers in New Jersey.
Other cardiovascular disease in Mountain Lakes
- Marc CohenNewark$762K
- Peter FarrugiaColts Neck$600K
- Felix Dailey-SterlingGuttenberg$568K
- Ramzan ZakirNew Brunswick$342K
- Richard KovachBrowns Mills$300K
- Andrea RussoCamden$293K
- John KostisNew Brunswick$225K
- Dilip ViswanathHaddon Heights$167K
- David PowellSpringfield$162K
- Fadi ChaabanWest Orange$161K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.